IAA
AKTX

Independent Advisor Alliance’s Akari Therapeutics AKTX Stock Holding History

Independent Advisor Alliance’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-427
Closed -$4.93K – 1598
2025
Q4 		$4.93K Buy
427
+155
+57% +$3.6K ﹤0.01% 999
2025
Q3 		$11K Buy
+272
New +$10.6K ﹤0.01% 944

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Independent Advisor Alliance's AKTX Position: Q1 2026 in Review

Independent Advisor Alliance sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 427 shares — an estimated $4.93K sold.

Independent Advisor Alliance first reported a position in AKTX in Q3 2025 and held it in 2 quarters. The position peaked at $11K in Q3 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Independent Advisor Alliance reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Independent Advisor Alliance sold 427 Akari Therapeutics shares in Q1 2026, an estimated $4.93K.
  • Independent Advisor Alliance first reported a position in Akari Therapeutics in Q3 2025 and held it in 2 quarters.
  • Independent Advisor Alliance's Akari Therapeutics position peaked at $11K in Q3 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Independent Advisor Alliance's 13F filing for Q1 2026, filed 12 May 2026.